Stock listing

LSE:POLB Poolbeg Pharma PLC Share Price

Home listing (LSE) of Poolbeg Pharma PLC

Follow Poolbeg Pharma PLC into a list and get an email when it puts out news.

Share price · LSE:POLB

6.15p GBX (pence) -0.25 (-3.9%)

Close on Nov 20, 2026

Past year +61.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
6.10p – 6.30p GBX (pence)Nov 20, 2026
Volume
998,803 sharesNov 20, 2026
Market cap
£46.95M GBPAt the close on Nov 20, 2026 · price × 763.4M shares outstanding
52-week range
3.30p – 9.30p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£132,845 GBPMedian day 1.03M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Poolbeg Pharma PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:POLB · Home6.15p GBX (pence)-0.25 (-3.9%)998,8036.20p6.30p6.10p6.40pClose on Nov 20, 2026
Frankfurt:7JN€0.063 EUR+0.002 (+3.3%)—€0.063€0.063€0.063€0.061Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:POLB · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
6.15p-0.25-3.9%6.20p6.30p6.10p998,803
6.40p-0.05-0.8%6.45p6.50p6.275p731,243
6.45p+0.35+5.7%6.10p6.50p5.90p1,646,207
6.10p+0.25+4.3%5.85p6.30p5.80p1,033,488
5.85p0.000.0%5.85p6.00p5.70p98,345
5.85p0.000.0%5.85p6.00p5.75p403,210
5.85p+0.05+0.9%5.80p6.00p5.73p221,855
5.80p-0.20-3.3%6.00p6.00p5.70p732,626
6.00p-0.05-0.8%6.05p6.05p5.90p325,787
6.05p+0.05+0.8%6.10p6.20p6.00p346,435
6.00p-0.40-6.3%6.30p6.30p6.00p1,102,742
6.40p0.000.0%6.40p6.45p6.30p185,026
6.40p0.000.0%6.40p6.50p6.30p215,082
6.40p-0.10-1.5%6.50p6.70p6.30p415,295
6.50p0.000.0%6.50p6.60p6.30p403,346
6.50p-0.15-2.3%6.65p6.695p6.332p304,561
6.65p0.000.0%6.65p6.697p6.50p460,013
6.65p-0.10-1.5%6.75p6.897p6.60p778,385
6.75p+0.09+1.4%6.45p6.897p6.335p1,528,062
6.66p+0.16+2.5%6.50p6.66p6.315p287,905
6.50p+0.25+4.0%6.25p6.70p6.10p1,865,446
6.25p0.000.0%6.25p6.40p5.894p2,248,702
6.25p0.000.0%6.25p6.40p6.10p584,172
6.25p-0.05-0.8%6.30p6.50p6.10p247,094
6.30p-0.30-4.5%6.40p6.50p6.10p929,307
6.60p+0.20+3.1%6.35p6.60p6.20p643,308
6.40p-0.10-1.5%6.50p6.60p6.30p1,580,972
6.50p-0.40-5.8%6.90p6.90p6.30p2,972,319
6.90p0.000.0%6.90p7.00p6.80p412,852
6.90p0.000.0%6.90p7.00p6.833p583,157
6.90p0.000.0%6.90p7.00p6.80p489,113
6.90p-0.30-4.2%7.15p7.21p6.80p3,245,625
7.20p+0.20+2.9%7.10p7.30p6.90p831,462
7.00p-0.18-2.5%7.10p7.30p6.90p594,920
7.18p-0.17-2.3%7.35p7.50p6.90p1,127,024
7.35p-0.05-0.7%7.35p7.50p7.20p1,029,441
7.40p0.000.0%7.35p7.50p7.20p554,887
7.40p+0.05+0.7%7.35p7.50p7.20p545,125
7.35p+0.25+3.5%7.10p7.60p7.052p6,680,306
7.10p-0.80-10.1%7.85p8.00p6.56p15,336,310
7.90p-1.15-12.7%9.15p9.30p7.50p10,213,737
9.05p+0.05+0.6%9.00p9.30p8.80p1,511,750
9.00p0.000.0%9.00p9.20p8.802p647,637
9.00p+0.15+1.7%8.85p9.20p8.70p2,766,692
8.85p-0.20-2.2%9.05p9.30p8.70p528,905
9.05p+0.10+1.1%8.95p9.30p8.80p1,241,303
8.95p+0.25+2.9%8.70p9.14p8.60p2,953,490
8.70p+0.30+3.6%8.40p8.80p8.30p720,027
8.40p+0.10+1.2%8.35p8.50p8.30p849,412
8.30p-0.10-1.2%8.40p8.55p8.30p2,518,226
8.40p+0.05+0.6%8.35p8.50p8.30p1,298,629
8.35p-0.05-0.6%8.40p8.50p8.30p331,576
8.40p+0.10+1.2%8.35p8.50p8.30p1,684,536
8.30p+0.05+0.6%8.25p8.44p8.20p1,407,519
8.25p-0.33-3.8%8.40p8.50p8.20p1,473,549
8.58p+0.34+4.1%8.25p8.58p8.20p4,492,676
8.24p-0.11-1.3%8.35p8.50p8.20p1,126,084
8.35p-0.25-2.9%8.45p8.80p8.30p2,166,547
8.60p+0.20+2.4%8.45p8.60p8.30p2,290,227
8.40p-0.20-2.3%8.65p9.00p8.40p3,210,258
8.60p0.000.0%8.60p8.80p8.40p1,816,142
8.60p+0.10+1.2%8.50p9.00p8.40p4,910,295
8.50p-0.30-3.4%8.80p9.00p8.40p3,090,204
8.80p-0.20-2.2%8.95p9.20p8.70p1,909,752
9.00p+0.35+4.0%8.65p9.20p8.50p2,656,061
Ticker
LSE:POLB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Latest news

POLB001 CRS Patent Granted in South Korea

Oct 6, 2026

Closed 7.20p (+2.9%) on Oct 6, 2026

POLB 001 TOPICAL trial recruitment update

Sep 28, 2026

Closed 7.35p (+3.5%) on Sep 28, 2026

Notification of major holdings

Jul 23, 2026

Closed 6.15p (+0.8%) on Jul 23, 2026

Placing to raise £3.5 million

Jul 14, 2026

Closed 6.05p (-13.6%) on Jul 14, 2026

POLB 001 patent granted in South Africa

Jun 30, 2026

Closed 6.85p (+1.5%) on Jun 30, 2026

All Poolbeg Pharma PLC news

Poolbeg Pharma PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 144 in all · newest Oct 6, 2026 · oldest 2021
Calls
12 calls with a replay · 12 with a transcript · latest Sep 24, 2026
Decks
16 decks · latest Oct 28, 2026

Where Poolbeg Pharma PLC is listed

ListingExchangeCountryCurrency
LSE:POLB · Home listing · This pageLSEUnited KingdomGBX
OTC:POLBFOTCUnited StatesUSD
Frankfurt:7JNFrankfurtGermanyEUR
Stuttgart:7JNStuttgartGermanyEUR

Valuation

Price/book 7.0× against a median of 2.9×: 7th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£42.13M GBP
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
7.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Poolbeg Pharma PLC · LSE:POLBUS$61.42MUS$55.12Mn/an/an/a7.0×n/a0.0×n/a
AlzeCure Pharma AB · OMXSTO:ALZCURUS$63.84MUS$62.72M21.3×6.6×25.6×7.1×31.6%0.0×n/a
Lytix Biopharma ASA · OSL:LYTIXUS$63.10MUS$53.73Mn/an/an/a7.1×n/a0.0×n/a
Neumora Therapeutics, Inc. · NASDAQ:NMRAUS$63.01MUS$30.65Mn/a1,916×n/a3.4×n/a2.9×1.07
ViGenCell, Inc. · KRX:308080US$61.45MUS$44.89Mn/a65.1×n/a2.1×n/a0.2×n/a
vTv Therapeutics Inc. · NASDAQ:VTVTUS$61.33M−US$15.84Mn/a−0.4×n/a0.9×−20.8%0.0×1.28
Oncopeptides AB · OMXSTO:ONCOUS$61.17MUS$58.97Mn/a6.3×n/a25.1×−223.6%5.4×n/a
HemoGenyx Pharmaceuticals PLC · LSE:HEMOUS$60.45MUS$56.88Mn/an/an/a10.7×n/a0.4×n/a
Genexine, Inc. · KRX:095700US$60.38MUS$44.48Mn/a12.0×n/a0.4×−650.0%0.0×n/a
ISU Abxis Co., Ltd. · KRX:086890US$60.20MUS$42.54Mn/a1.1×n/a0.7×−16.0%0.0×n/a
GlycoNex, Inc. · TPEX:4168US$59.92MUS$57.20Mn/a84.9×n/a2.3×n/a0.6×n/a
Median of the othersUS$61.25MUS$49.31M21.3×9.3×25.6×2.9×−20.8%0.1×1.18

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
19.00 GBX · Analysts' mean
EPS, year to Dec 2026
-0.007 · 2 analysts

Team and board

Officers

OfficerRole
Jeremy SkillingtonChief Executive Officer
Ian O’ConnellChief Financial Officer
Carol DaltonVP, Investor Relations & Public Relations
Bruno SpederVP of Regulatory Affairs
Meena AroraVP, Medical Affairs & Development
Cathal FrielExecutive Chair

Board

DirectorRole
Cathal FrielExecutive Chair
Brendan BuckleyNon Executive Director
Eddie GibsonNon-Executive Director
Luke O’NeillNon-Executive Director

Events

Calls

CallWhenStatus
Poolbeg Pharma (LSE:POLB) — Company PresentationThu, Sep 24, 2026 · 9:00 AM ETReplay
Poolbeg Pharma (LSE:POLB) Q4 2025 Earnings CallTue, Apr 28, 2026 · 12:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — POLB 001 Phase 2a Trial UpdateMon, Sep 29, 2025 · 12:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — Company PresentationMon, Jun 23, 2025 · 12:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — Investor PresentationWed, Feb 26, 2025 · 12:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — Company PresentationTue, Apr 30, 2024 · 1:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — POLB 001 UpdateWed, Jan 17, 2024 · 1:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — Company UpdateFri, Nov 10, 2023 · 7:30 AM ETReplay
Poolbeg Pharma (LSE:POLB) — Full Year ResultsThu, Mar 30, 2023 · 5:00 AM ETReplay
Poolbeg Pharma (LSE:POLB) — Investor PresentationWed, Dec 14, 2022 · 12:30 PM ETReplay
All 12 calls
CallWhenStatus
Poolbeg Pharma (LSE:POLB) — Interim ResultsTue, Sep 06, 2022 · 1:00 PM ETReplay
Poolbeg Pharma (LSE:POLB) — Investor PresentationThu, Mar 03, 2022 · 1:00 PM ETReplay

Results days

QuarterResultsShare move
Q4 2025Feb 26, 2026−4.3%
Q2 2025Sep 29, 2025−7.7%
Quarter to Mar 31, 2025May 27, 2025+53.1%
Q1 2023Apr 12, 2023−2.4%
Q2 2022Sep 6, 2022+5.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck24 slidesOct 28, 2026
Investor Presentation (October 2026)Investor deck38 slidesOctober 2026
Q4 2025 Earnings PresentationEarnings35 slidesApr 28, 2026
Investor Presentation (June 2025)Investor deck34 slidesJune 2025
Investor Presentation (May 2025)Investor deck32 slidesMay 2025
Investor Presentation (May 2025)Investor deck29 slidesMay 2025
Investor Presentation (May 2024)Investor deck38 slidesMay 2024
Investor Presentation (July 2023)Investor deck28 slidesJuly 2023
Investor Presentation (January 2023)Investor deck46 slidesJanuary 2023
Investor Presentation (February 2022)Investor deck26 slidesFebruary 2022
All 16 decks
DeckKindSlidesDate
Investor Presentation (January 2022)Investor deck25 slidesJanuary 2022
Investor Presentation (December 2021)Investor deck21 slidesDecember 2021
Investor Presentation (November 2021)Investor deck21 slidesNovember 2021
Investor Presentation (October 2021)Investor deck22 slidesOctober 2021
Investor Presentation (October 2021)Investor deck22 slidesOctober 2021
Investor Presentation (July 2021)Investor deck21 slidesJuly 2021

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares
Closed: £3.5M raised · GBX 6 a share · OAK Securities
Dealers: OAK Securities (lead)
Buyers: Cathal Friel (£250,000 subscription)
Insiders: Executive Chair Cathal Friel subscribed a further £250,000
Use of proceeds: Fund the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial to completion; strengthen partnering position
Sep 29, 2026US$4.63M
Private placement of new ordinary shares
Made bigger: £4.87M · GBX 2.5 a share · Shore Capital +1
Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited (lead)
Buyers: Cathal Friel (4,000,000 new Ordinary Shares, investment of £100,000)
Insiders: Executive Chair Cathal Friel subscribed for 4,000,000 new Ordinary Shares, an investment of £100,000
Use of proceeds: Phase 2a trial of POLB 001 for cancer immunotherapy-induced CRS, oral GLP-1 proof-of-concept trial, cash runway into 2027
Jun 23, 2025US$6.56M
BookBuild Offer Shares (new ordinary shares)
Made bigger: £150,000 · GBX 2.5 a share · Shore Capital +1
Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited
Use of proceeds: Fund POLB 001 Phase 2a trial and oral GLP-1 proof of concept trial, providing runway into 2027
May 22, 2025US$201,316

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue00000
Cost of revenue59.0K114.0K26.0K26.0K18.0K
Gross profit-59.0K-114.0K-26.0K-26.0K-18.0K
Research and development1.52M1.38M1.68M2.20M414.0K
Selling, general and administrative4.89M5.26M3.38M3.06M2.03M
Operating income-6.42M-6.62M-5.04M-4.99M-2.38M
Depreciation and amortization59.0K114.0K26.0K26.0K18.0K
EBITDA-6.36M-6.50M-5.01M-4.96M-2.36M
Interest expense0
Income before tax-5.77M-5.94M-4.50M-4.78M-2.34M
Income tax-79.0K154.0K-574.0K-91.0K42.0K
Net income-5.70M-5.79M-3.93M-4.69M-2.34M
Earnings per share, basic-0.01-0.01-0.01-0.01-0.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents7.71M7.82M12.2M16.2M20.9M
Receivables364.0K519.0K700.0K962.0K8.00K
Inventory-1.33M-9620
Current assets8.27M8.56M13.5M17.2M21.5M
Total assets9.94M10.2M15.4M19.3M23.0M
Accounts payable151.0K165.0K79.0K293.0K79.0K
Current liabilities1.34M974.0K986.0K966.0K438.0K
Total liabilities1.34M974.0K986.0K966.0K438.0K
Shareholders' equity8.60M9.27M14.4M18.3M22.6M
Shares outstanding602.7M500.0M497.6M500.0M500.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-4.51M-4.65M-4.38M-4.37M-2.15M
Capital spending-4.51M-129.0K-175.0K-597.0K-81.0K
Free cash flow-4.84M-4.78M-4.02M-4.96M-2.23M
Cash from investing-80.0K299.0K359.0K-388.0K-81.0K
Cash from financing4.48M23.2M
Change in cash-111.0K-4.35M-4.02M-4.76M20.9M

Open Financials

Cap table

Built by 6ix from Poolbeg Pharma PLC’s releases · as of Sep 29, 2026

Common shares
763,437,106
Fully diluted
763,437,106

Fully diluted

LineSharesAs of
Common shares763,437,106Sep 29, 2026

Share count over time

CountShares
Sep 29, 2026763,437,106

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cathal Friel
Other companies: European Green Transition PLC (Co-Founder & Executive Chair · Since at least Apr 14, 2025)
Executive Chair · Since at least Sep 29, 2026
Brendan BuckleyNon Executive Director · Since at least May 13, 2026
Bruno SpederVP of Regulatory Affairs · Since at least May 26, 2026
Carol DaltonVP, Investor Relations & Public Relations · Since at least Nov 4, 2026
Eddie GibsonNon-Executive Director · Since at least Nov 4, 2026
Ian O’ConnellChief Financial Officer · Since at least Oct 6, 2026
Jeremy SkillingtonChief Executive Officer · Since at least Oct 6, 2026
Luke O’NeillNon-Executive Director · Since at least Mar 12, 2026
Meena AroraVP, Medical Affairs & Development · Since at least May 13, 2026

Open People

Log in to ask 6ix AI your own questions about Poolbeg Pharma PLC.